Based upon frequent down regulation of INGs in cancer cells and their biological relationship with p53, loss of INGs may also affect breast cancer cell response to chemotherapeutic agents as suggested for vincristine in brain tumors [10] and for paclitaxel and etoposide in osteosarcoma cells [11]. The gene discussed is TP53; the disease is breast carcinoma.